Meeting the GLP-1 Challenge with High-Resolution Mass Spec - Top-Institutions - MDSpire

Meeting the GLP-1 Challenge with High-Resolution Mass Spec

Veloxity Labs and SCIEX team up to advance peptide bioanalysis; here, the teams discuss how the GLP-1 boom is reshaping workflows and raising the bar for analytical performance

  • By

  • James Strachan

  • February 25, 2026

  • 7 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts Institute of Technology (MIT) - Center for Biomedical Innovation
    Massachusetts Institute of Technology (MIT) - Center for Biomedical Innovation

    Cambridge, MA

    Key Differentiators

    • Analytical Chemistry
    • Pharmaceutical Sciences
    • Mass Spectrometry

  • #2

    University of California, San Francisco (UCSF) - Department of Pharmaceutical Chemistry
    University of California, San Francisco (UCSF) - Department of Pharmaceutical Chemistry

    San Francisco, CA

    Key Differentiators

    • Pharmaceutical Chemistry
    • Clinical Pharmacology
    • Mass Spectrometry

  • #3

    Johns Hopkins University - Department of Pharmacology and Molecular Sciences
    Johns Hopkins University - Department of Pharmacology and Molecular Sciences

    Baltimore, MD

    Key Differentiators

    • Pharmacology
    • Mass Spectrometry
    • Peptide Therapeutics

  • #4

    University of Michigan - College of Pharmacy
    University of Michigan - College of Pharmacy

    Ann Arbor, MI

    Key Differentiators

    • Pharmaceutical Sciences
    • Analytical Chemistry
    • Mass Spectrometry

  • #5

    Stanford University - Department of Chemistry
    Stanford University - Department of Chemistry

    Stanford, CA

    Key Differentiators

    • Analytical Chemistry
    • Mass Spectrometry
    • Pharmaceutical Sciences

Original Source(s)

Meeting the GLP-1 Challenge with High-Resolution Mass Spec

  • by James Strachan

  • February 25, 2026

Related Content

The Impact of Physical Activity Levels on Sexual Function in Breast Cancer Survivors: An Integrative Review

Sexual dysfunction is a lasting effect of treatment and can impact the quality of life of breast cancer survivors. This review examined the impact of different levels (none/low, moderate, and high) of physical activity on sexual outcomes in breast cancer survivors.

Multi-omics analysis identifies stemness-driven molecular subtypes, prognostic signature, epigenetic target APCDD1, and drug candidate Leflunomide in Wilms tumor

Case Report: Ovarian dysgerminoma mimicking a sex cord-stromal tumor with hyperandrogenism: diagnostic challenges and molecular insights